Strides Pharma Science quarterly results and financials

Strides Pharma Science (STAR)₹1,002−3.25%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Sep 2026 quarter (consolidated), Strides Pharma Science reported sales of ₹1,435 Cr, up 17.1% from Sep 2025, and net profit of ₹133 Cr, up 1.6% year on year. For the year to Mar 2026, sales were ₹4,873 Cr and net profit ₹573 Cr.

Sales (Sep 2026): ₹1,435 Cr
Net profit (Sep 2026): ₹133 Cr
Sales (FY Mar 2026): ₹4,873 Cr
Net profit (FY Mar 2026): ₹573 Cr
EPS (Sep 2026): ₹14.21
Borrowings (Mar 2026): ₹1,754 Cr

Company filings, consolidated accounts; latest reported quarter Sep 2026

Strides Pharma Science quarterly results

₹ crore unless stated; each column is a quarter.

Strides Pharma Science Quarterly results
	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	1,010	1,049	1,057	1,172	1,158	1,194	1,124	1,225	1,199	1,327	1,270	1,435
Expenses	876	874	865	982	942	973	902	989	958	1,083	1,036	1,179
Operating Profit	129	169	188	184	209	218	217	230	235	239	228	250
OPM %	12.9%	16.0%	17.9%	16.0%	18.0%	18.0%	19.0%	18.9%	20.0%	17.9%	17.9%	18.0%
Other Income	59.93	−26.98	3,297	24.99	4.01	−11.99	0.00	17.98	104	2.99	67.98	2.99
Interest	70.09	71.07	73.13	74.12	52.06	50.03	47.09	46.09	43.05	42.07	41.06	47.03
Depreciation	49.18	48.16	47.14	48.12	48.13	49.18	49.15	50.13	51.19	53.20	56.17	57.15
Profit before tax	69.89	22.96	3,367	85.82	114	106	122	153	245	148	200	150
Tax %	22.9%	55.0%	1.0%	15.9%	20.9%	20.0%	12.9%	13.9%	15.0%	12.9%	17.0%	11.0%
Exceptional items	34.96	−9.98	3,269	−2.99	−1.99	−21.97	−6.99	−6.99	−2.99	−5.99	51.94	−0.99
Net Profit	53.82	9.96	3,335	71.69	89.71	85.64	106	131	207	128	164	133
EPS (Rs)	5.41	1.99	364.89	7.82	9.55	8.92	10.82	13.86	21.95	13.78	17.03	14.21

Strides Pharma Science profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Strides Pharma Science Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	2,870	2,765	2,856	2,185	2,761	3,329	3,080	3,700	3,907	4,580	4,873	5,231
Expenses	2,485	2,228	2,447	1,981	2,336	2,778	3,198	3,541	3,361	3,762	3,930	4,257
Operating Profit	373	525	397	197	413	536	−131	145	526	801	922	953
OPM %	12.9%	18.9%	13.9%	9.0%	15.0%	15.9%	−4.3%	3.9%	14.0%	18.0%	18.9%	18.2%
Other Income	62.92	291	643	303	−42.99	109	−112	91.98	−99.94	3,309	124	178
Interest	168	183	196	79.13	156	150	177	261	280	249	179	173
Depreciation	131	126	154	117	175	207	234	244	215	193	203	218
Profit before tax	137	508	689	302	41.94	288	−652	−268	−64.89	3,669	668	742
Tax %	31.0%	12.0%	1.0%	−9.1%	27.0%	11.0%	−27.1%	−21.0%	45.0%	2.0%	13.9%	—
Exceptional items	−18.97	−30.97	−33.94	27.93	−25.95	41.90	−232	−12.98	−219	72.90	−9.99	41.97
Net Profit	94.71	444	681	329	30.87	257	−472	−211	−93.63	3,583	573	634
EPS (Rs)	12.16	44.72	74.35	36.32	4.07	29.97	−51.31	−22.47	−7.69	389.93	60.35	66.97
Dividend payout %	41.0%	10.0%	3.0%	8.0%	345.0%	8.0%	0.0%	−7.0%	−33.0%	1.0%	8.0%	—

Strides Pharma Science balance sheet

₹ crore, at each year end.

Strides Pharma Science Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	60.23	89.30	89.31	90.36	90.30	90.35	90.36	90.36	90.30	92.31	92.30	92.27
Reserves	1,083	2,567	2,654	2,370	2,556	2,433	2,683	2,264	2,117	2,032	2,456	3,007
Borrowings	891	3,540	3,693	2,515	3,217	2,231	2,346	3,019	3,026	2,516	1,878	1,754
Other Liabilities	440	1,217	1,606	1,609	1,946	1,376	1,853	1,563	1,359	1,163	1,505	1,950
Total Liabilities	2,474	7,412	8,042	6,584	7,809	6,129	6,972	6,937	6,591	5,802	5,931	6,804
Fixed Assets	701	2,681	2,979	2,976	3,648	2,099	2,220	2,345	2,310	1,865	1,898	2,101
CWIP	170	812	777	617	452	412	446	290	150	161	206	446
Investments	630	1,342	1,525	588	702	549	697	540	490	303	409	291
Other Assets	972	2,578	2,761	2,402	3,008	3,070	3,609	3,762	3,641	3,473	3,417	3,966
Inventories	208	613	733	552	874	784	1,202	1,174	1,147	1,127	1,278	1,635
Trade receivables	392	1,036	1,000	886	990	935	1,111	1,211	1,304	1,146	1,208	1,294
Cash & equivalents	147	311	328	302	516	236	180	186	315	190	137	212
Total Assets	2,474	7,412	8,042	6,584	7,809	6,129	6,972	6,937	6,591	5,802	5,931	6,804

Strides Pharma Science cash flow

₹ crore, for each year.

Strides Pharma Science Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	82.97	72.97	288	187	60.01	205	481	−258	44.01	701	683	703
Cash from investing activity	49.94	−2,201	−1,220	569	−145	1,318	−521	−119	302	−150	−89.87	−173
Cash from financing activity	−422	2,946	338	−1,017	194	−1,712	−16.01	421	−214	−694	−644	−453
Net cash flow	−289	814	−598	−260	110	−184	−56.14	45.11	134	−142	−48.15	76.29
Capex	242	369	683	403	329	150	297	143	95.02	118	248	418
Free cash flow	−157	−294	−388	−213	−257	58.16	189	−327	−43.14	674	507	292
CFO / OP %	61.0%	39.9%	66.0%	61.0%	59.0%	60.0%	60.0%	199.0%	−30.0%	128.0%	77.0%	84.0%

Strides Pharma Science ratios

Working-capital days and returns, by year.

Strides Pharma Science Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	120	133	133	114	166	125	123	145	130	108	97	98
Inventory days	136	150	210	147	295	255	330	286	258	236	237	306
Days payable	153	188	221	188	299	259	323	260	220	178	190	244
Cash conversion cycle	102	92	120	71	160	119	128	168	165	164	141	157
Working capital days	−91	6	−122	−4	−70	−70	−22	−28	−11	−19	24	38
ROCE %	57.0%	8.0%	11.0%	16.0%	2.0%	5.0%	8.0%	−5.0%	0.0%	7.0%	15.0%	18.0%

Strides Pharma Science: frequently asked questions

What are the latest quarterly results of Strides Pharma Science?

For the Sep 2026 quarter, Strides Pharma Science reported sales of ₹1,435 Cr, up 17.1% year on year and net profit of ₹133 Cr, up 1.6% year on year. The operating margin was 18.0%.

What is the annual revenue of Strides Pharma Science?

Strides Pharma Science's sales for the year to Mar 2026 were ₹4,873 Cr; over the last twelve months they were ₹5,231 Cr.

What is the net profit of Strides Pharma Science?

Net profit for the year to Mar 2026 was ₹573 Cr, and ₹634 Cr over the last twelve months. Earnings per share over the same trailing period were ₹66.97.

How much debt does Strides Pharma Science have?

Strides Pharma Science reported borrowings of ₹1,754 Cr at Mar 2026, against cash and equivalents of ₹212 Cr.

What is the free cash flow of Strides Pharma Science?

Cash from operations was ₹703 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹292 Cr.

Loading…